Niklas Schmedt

Ingelheim Am Rhein, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.

Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.

Journal: Journal of the American Heart Association

Published: March 10, 2026

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

Journal: Cardiovascular diabetology

Published: January 04, 2026

Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.

Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: June 20, 2025

Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.

Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.

Journal: Diabetes, obesity & metabolism

Published: February 13, 2025

Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.

Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.

Journal: Diabetes, obesity & metabolism

Published: January 20, 2025

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.

Journal: JAMA ophthalmology

Published: December 05, 2024

Incident heart failure and recurrent coronary events following acute myocardial infarction.

Incident heart failure and recurrent coronary events following acute myocardial infarction.

Journal: European heart journal

Published: March 27, 2024

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Journal: Cardiovascular diabetology

Published: March 19, 2024

Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.

Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.

Journal: Diabetes care

Published: February 08, 2024

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.

Journal: Journal of general internal medicine

Published: January 19, 2024

Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.

Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.

Journal: International journal of cardiology

Published: December 18, 2023

Effectiveness and safety of empagliflozin: final results from the EMPRISE study.

Effectiveness and safety of empagliflozin: final results from the EMPRISE study.

Journal: Diabetologia

Published: October 18, 2023

Showing 1-12 of 42

Last Updated: 09/26/2026